Arbutus Biopharma Corp to Discuss Preliminary Phase 1a/1b Clinical Trial Results for AB-506 - Call Transcript
Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation conference call. (Operator Instructions) As a reminder, this call will be recorded. I would now like to introduce your host for today's conference. Ms. Pam Murphy, you may begin.
Good afternoon. On the call from the Arbutus Executive Team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Mike Sofia, Chief Scientific Officer; and David Hastings, Chief Financial Officer. Bill will begin with a few opening remarks followed by Gaston, who will discuss the preliminary Phase Ia/Ib results for AB-506 which has -- which were announced earlier this afternoon. We'll then open up the call for Q&A.
Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements including statements regarding expectations for Arbutus' proprietary HBV pipeline including clinical results and time lines for our 2 lead
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |